JAK2 and Splenomegaly: However, since the introduction of ruxolitinib, an oral Janus kinase (JAK) 1/JAK2 inhibitor that effectively reduces splenomegaly in 42% of patients and improves symptoms, the indication for splenectomy is highly improbable [17, 18].